Chen, Hailin http://orcid.org/0000-0003-1648-0427
Yu, Tengteng
Lin, Liang
Xing, Lijie
Cho, Shih-Feng
Wen, Kenneth
Aardalen, Kimberly
Oka, Adwait
Lam, Joni
Daley, Mike http://orcid.org/0000-0003-4673-8214
Lu, Haihui
Munshi, Nikhil http://orcid.org/0000-0002-7344-9795
Anderson, Kenneth C.
Tai, Yu-Tzu http://orcid.org/0000-0001-6199-3569
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA100707, P01-155258, P50 CA100707, P01CA155258, R01-CA178264, RO1 CA 207237, P50 CA100707, R01CA207237, P01 CA155258, RO1 CA178264)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
the Paula and Rodger Riney Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
the Adelson Medical Research Foundation and the Paula and Rodger Riney Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
This work was supported in part by the Adelson Medical Research Foundation and the Paula and Rodger Riney Foundation.
Article History
Received: 17 May 2022
Revised: 27 July 2022
Accepted: 29 July 2022
First Online: 16 August 2022
Competing interests
: KA, AO, JL, MD, HL are employees of Novartis Institutes for Biomedical Research (NIBR) and have stock and/or stock interests in NIBR. NCM serves on advisory boards to Millennium-Takeda, Celgene, and Novartis and is a Scientific Founder of Oncopep. NCM serves on advisory boards/consultant to Takeda, BMS, Celgene, Janssen, Amgen, AbbVie, Oncopep, Karyopharm, Adaptive Biotechnology, and Novartis and holds equity ownership in Oncopep. KCA serves on advisory boards to Pfizer, Amgen, AstraZeneca, Janssen, Precision Biosciences, Window, and Starton, and is a scientific founder of OncoPep, C4 Therapeutics, Raqia, and NextRNA. All other authors declare no competing financial interests.